Deferoxamine br Curran Jr WJ Paulus
 Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452–60.  St James S, Grassberger C, Lu HM. Considerations when treating lung cancer with passive scatter or active scanning Deferoxamine therapy. Transl Lung Cancer Res 2018;7:210–5.
 Chang JY, Zhang X, Knopf A, Li H, Mori S, Dong L, et al. Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee. Int J Radiat Oncol Biol Phys 2017;99:41–50.
 Chang JY, Li H, Zhu XR, Liao Z, Zhao L, Liu A, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys 2014;90:809–18.  Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol 2018;8:58–65.
 Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated
 Cao W, Lim G, Li X, Li Y, Zhu XR, Zhang X. Incorporating deliverable monitor unit constraints into spot intensity optimization in intensity-modulated proton therapy treatment planning. Phys Med Biol 2013;58:5113–25.  Li Y, Niemela P, Liao L, Jiang S, Li H, Poenisch F, et al. Selective robust optimization: a new intensity-modulated proton therapy optimization strategy. Med Phys 2015;42:4840–7.  Zhang X, Li X, Quan EM, Pan X, Li Y. A methodology for automatic intensity-modulated radiation treatment planning for lung cancer. Phys Med Biol 2011;56:3873–93.
 Li H, Zhu XR, Zhang X. Reducing dose uncertainty for spot-scanning proton beam therapy of moving tumors by optimizing the spot delivery sequence. Int J Radiat Oncol Biol Phys 2015;93:547–56.  Stata. Release 15 ed. College Station, TX: StataCorp LP; 2017. p. Statistical Software.
 Nguyen QN, Ly NB, Komaki R, Levy LB, Gomez DR, Chang JY, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol 2015;115:367–72.  Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, et al. Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study. JAMA Oncol 2017;3: e172032.
 Liao Z, Lee JJ, Komaki R, Gomez DR, O’Reilly MS, Fossella FV, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 2018;36:1813–22.  Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys 2010;77:357–66.
 Haque W, Verma V, Fakhreddine M, Butler EB, Teh BS, Simone 2nd CB. Trends in cardiac mortality in patients with locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2018;100:470–7.
142 Outcomes after IMPT for NSCLC
 Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol 2017;125:293–300.
 Yegya-Raman N, Wang K, Kim S, Reyhan M, Deek MP, Sayan M, et al. Dosimetric predictors of symptomatic cardiac events after conventional-dose chemoradiation therapy for inoperable NSCLC. J Thorac Oncol 2018;13:1508–18.